Literature DB >> 12528012

Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea.

Linda A Parker1, Raphael Mechoulam, Coralynn Schlievert, Laura Abbott, Melissa L Fudge, Page Burton.   

Abstract

RATIONALE: Marijuana has been reported to suppress nausea produced by chemotherapy treatment in human cancer patients. Although there is abundant evidence that cannabinoid agonists attenuate vomiting in emetic species, there has been little experimental evidence of their anti-nausea potential. Considerable evidence suggests that conditioned rejection reactions in rats reflect nausea. The present experiments evaluated the potential of low doses of the cannabinoid agonists, delta-9-tetrahydrocannabinol (THC; 0.5 mg/kg, i.p.), and HU-210 (0.001 mg/kg and 0.01 mg/kg, i.p.), and the CB(1) antagonist SR-141716A in modulating the establishment and the expression of lithium-induced conditioned rejection reactions in rats.
OBJECTIVES: To evaluate the effect of cannabinoids on conditioned rejection reactions, a rat model of nausea.
METHODS: In experiments 1 and 2, respectively, rats were injected with cannabinoid agonists, THC (0.5 mg/kg, i.p.) and HU-210 (0.001, 0.005 or 0.01 mg/kg), 30 min prior to exposure to 0.1% saccharin solution by intraoral infusion. Immediately following saccharin exposure, they were injected with 20 ml/kg 0.15 M lithium chloride or saline. On each of two test trials, the rats were injected with the cannabinoid or vehicle 30 min prior to exposure to saccharin. In experiment 3, rats were injected with the CB(1) antagonist, SR-141716A (2.5 mg/kg) or a combination of SR-141716A and HU-210 (0.01 mg/kg) 30 min prior to an infusion of saccharin followed by injection of lithium or saline. They were given a single drug-free test trial. Experiment 4 replicated and extended the findings of experiment 3.
RESULTS: delta-9-THC and HU-210 interfered with the establishment and the expression of lithium-induced conditioned rejection reactions. The suppressive effect of HU-210 on rejection reactions was reversed by pretreatment with SR-141716A. Administration of SR-141716A prior to conditioning potentiated lithium-induced conditioned rejection reactions.
CONCLUSIONS: These results indicate that the establishment and the expression of lithium-induced conditioned rejection reactions are suppressed by pretreatment with cannabinoid agents. These effects appear to be mediated by their action on the CB(1) receptor, because they are reversed by pretreatment with SR-141716A. Finally, our results suggest that endogenous cannabinoids play a role in modulation of nausea, because the antagonist potentiated lithium-induced nausea.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12528012     DOI: 10.1007/s00213-002-1329-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  CB1 cannabinoid receptor induction in experimental stroke.

Authors:  K L Jin; X O Mao; P C Goldsmith; D A Greenberg
Journal:  Ann Neurol       Date:  2000-08       Impact factor: 10.422

2.  The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.

Authors:  Nissar A Darmani
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

3.  Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity.

Authors:  M Shen; S A Thayer
Journal:  Mol Pharmacol       Date:  1998-09       Impact factor: 4.436

4.  Cannabimimetic activity in rats and pigeons of HU 210, a potent antiemetic drug.

Authors:  F Ferrari; A Ottani; D Giuliani
Journal:  Pharmacol Biochem Behav       Date:  1999-01       Impact factor: 3.533

5.  2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.

Authors:  L Hanus; S Abu-Lafi; E Fride; A Breuer; Z Vogel; D E Shalev; I Kustanovich; R Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

6.  Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea.

Authors:  C L Limebeer; L A Parker
Journal:  Neuroreport       Date:  1999-12-16       Impact factor: 1.837

7.  Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.

Authors:  N A Darmani
Journal:  Neuropsychopharmacology       Date:  2001-02       Impact factor: 7.853

8.  Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats.

Authors:  Linda A Parker; Raphael Mechoulam; Coralynne Schlievert
Journal:  Neuroreport       Date:  2002-04-16       Impact factor: 1.837

9.  Effects of 5-hydroxytryptamine on discharge of vagal mucosal afferent fibres from the upper gastrointestinal tract of the ferret.

Authors:  L A Blackshaw; D Grundy
Journal:  J Auton Nerv Syst       Date:  1993-10

10.  Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants.

Authors:  A J Hampson; M Grimaldi; J Axelrod; D Wink
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

View more
  36 in total

Review 1.  Involvement of cannabinoid receptors in gut motility and visceral perception.

Authors:  Pamela J Hornby; Stephen M Prouty
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

2.  Effect of combined oral doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea in rat models.

Authors:  Erin M Rock; Cassidy Connolly; Cheryl L Limebeer; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2016-07-20       Impact factor: 4.530

3.  Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus).

Authors:  L D O'Brien; C L Limebeer; E M Rock; G Bottegoni; D Piomelli; L A Parker
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

4.  Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat.

Authors:  Shelley K Cross-Mellor; Klaus-Peter Ossenkopp; Daniele Piomelli; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2006-11-17       Impact factor: 4.530

5.  The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats.

Authors:  Kelly S Sink; Peter J McLaughlin; Jodi Anne T Wood; Cara Brown; Pusheng Fan; V Kiran Vemuri; Yan Peng; Yan Pang; Teresa Olszewska; Teresa Olzewska; Ganesh A Thakur; Alex Makriyannis; Linda A Parker; John D Salamone
Journal:  Neuropsychopharmacology       Date:  2007-06-20       Impact factor: 7.853

Review 6.  Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions.

Authors:  John D Salamone; Peter J McLaughlin; Kelly Sink; Alexandros Makriyannis; Linda A Parker
Journal:  Physiol Behav       Date:  2007-04-14

7.  The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat.

Authors:  Erin M Rock; Cheryl L Limebeer; Raphael Mechoulam; Daniele Piomelli; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2007-11-09       Impact factor: 4.530

Review 8.  Endocannabinoids and the gastrointestinal tract: what are the key questions?

Authors:  G J Sanger
Journal:  Br J Pharmacol       Date:  2007-09-03       Impact factor: 8.739

9.  Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping.

Authors:  Erin M Rock; Cheryl L Limebeer; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2015-09-18       Impact factor: 4.530

Review 10.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.